Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.
Inflammatory joint diseases are responsible of chronic systemic inflammation, joint degradations, deformities, and altered quality of life. Patients suffering from chronic rheumatic diseases also present increased bone fragility and increased fracture risk. Registration of biologic therapies has deeply modified care in rheumatic diseases, especially in rheumatoid arthritis and ankylosing spondylitis. The available biologics are the anti proinflammatory cytokine therapies (TNFα blockers, anakinra and tocilizumab) and the biologics active on T cell activation (abatacept and rituximab). These drugs succeeded in blocking disease activity and joint degradation. They are also able to stop systemic bone loss among patients with inflammatory rheumatic diseases. In this review, we present the current understanding of the inflammatory-induced bone loss and the skeletal effects of biologic therapies in inflammatory joint diseases.
Department of Rheumatology, INSERM U831-Université de Lyon, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon 69003, France. cyril.confavreux@inserm.fr
C B
CB
Confavreux
R D
RD
Chapurlat
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy*
D018501:Antirheumatic Agents; D001688:Biological Products; D016207:Cytokines